An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Millennium
- 12 Aug 2017 Data from this and other trials (NCT00963820, NCT01217957, NCT01564537) was used to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM, results published in the Targeted Oncology
- 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
- 23 Jul 2013 Planned number of patients changed from 70 to 63 as reported by ClinicalTrials.gov.